Inogen, a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the release to market of its innovative Inogen One G4 portable oxygen concentrator.
The ultra-portable device is the smallest and lightest oxygen concentrator that the Company has ever produced, and the Company expects the product to be embraced by long-term oxygen therapy users worldwide.
At only 2.8 pounds, the Inogen One G4 is small and light-weight, allowing it to seamlessly fit into the lifestyles of active oxygen therapy patients. Compared to the popular Inogen One G3, the Inogen One G4 is more than 40% lighter and is approximately half the size.
Weighing less than commonly used oxygen tanks, the Inogen One G4 can easily be carried over the shoulder, worn on the hip or belt, or carried in a convenient backpack with optional accessories.
With three flow settings and Inogen’s standard Intelligent Delivery Technology, the Inogen One G4 was designed to meet the clinical needs of greater than 85% of patients that express an interest in the Company’s products as a single solution for oxygen therapy – at home, away, and for travel.
Other patient-preferred features include a long battery life of up to 6 hours with the optional double battery, a large LCD screen, and very quiet operation.
The Inogen One G4 represents a step forward in innovation within the oxygen therapy market. The Company believes that the Inogen One G4 boasts the highest oxygen output per pound of weight of any oxygen concentrator currently available in the supplemental oxygen therapy US homecare market.
It is Inogen’s mission to push the boundaries of conventional design and to develop innovative and patient-preferred oxygen technology so that patients can reclaim their freedom and independence.
"The Inogen One G4 exemplifies Inogen’s spirit of innovation and dedication to designing products specifically for the end consumer, the oxygen therapy user," said Raymond Huggenberger, Inogen’s CEO.
"We are extremely proud of the level of innovation that we are delivering to patients, and we look forward to hearing about the lives changed because of the Inogen One G4."
The Inogen One G4 has been released for sale to oxygen therapy patients in the Company’s direct-to-consumer sales channel and is expected to be made available to additional sales channels, including domestic and international business-to-business channels (pending receipt of any required foreign regulatory approvals), through a controlled rollout process over the coming months.
In addition, on May 24th 2016 the Department of Transportation and the Federal Aviation Administration published a final rule concerning the acceptance criteria for portable oxygen concentrators used on board aircraft.
The final rule replaces the current product by product approval process and allows commercial aircraft passengers to use a portable oxygen concentrator on board if the portable concentrator satisfies certain acceptance criteria and the product has a label indicating conformance with the acceptance criteria.
The Inogen One G4 satisfies the necessary acceptance criteria; therefore the expected date that passengers will be able to travel on board commercial aircraft with the Inogen One G4 is the final rule implementation date, which is August 22nd, 2016.
In the meantime, Inogen One G4 users are encouraged to contact the Company if they wish to travel via commercial aircraft to discuss options for traveling with the Inogen One G3 that is currently approved by the FAA.